Safety Study of APR-246 in Patients With Refractory Hematologic Cancer or Prostate Cancer

NCT00900614 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Hematologic Neoplasms
Prostatic Neoplasms

Interventions

DRUG: APR-246

Sponsor

Aprea Therapeutics